Brain tDCS as a disease-modifying treatment of MS: A pilot study in a chronic EAE model

被引：0
|
作者：
Santangelo, R. [1 ]
Castoldi, V. [1 ]
Finardi, A. [1 ]
Cursi, M. [1 ]
Camaleonti, L. [1 ]
Comi, G. [1 ]
Furlan, R. [1 ]
Leocani, L. [1 ]
机构：
[1] Osped San Raffaele, Milan, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1102
引用
收藏
页码：569 / 570
页数：2
相关论文
共 50 条
  • [31] Disease course and disease-modifying treatment in men and women with early MS from the German NationMS cohort
    Gisevius, Barbara
    Tokic, Marianne
    Poser, Philip
    Fisse, Anna Lena
    Grueter, Thomas
    Berthele, Achim
    Giglhuber, Katrin
    Flaskamp, Martina
    Fleischer, Vinzenz
    Bittner, Stefan
    Groppa, Sergiu
    Luessi, Felix
    Bayas, Antonios
    Meuth, Sven
    Heesen, C.
    Trebst, Corinna
    Wildemann, Brigitte
    Bergh, Florian Then
    Antony, Gisela
    Kuempfel, Tania
    Paul, Friedemann
    Nischwitz, Sandra
    Tumani, Hayrettin
    Zettl, Uwe K.
    Hemmer, Bernhard
    Wiendl, Heinz
    Zipp, Frauke
    Timmesfeld, Nina
    Gold, Ralf
    Motte, Jeremias
    Salmen, Anke
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 435 - 436
  • [32] Changes of disease characteristics and disease-modifying treatment within one year in the National German MS cohort
    Ambrosius, B.
    Hessler, N.
    Antony, G.
    Konig, I. R.
    Hoshi, M-M.
    Aly, L.
    Luessi, F.
    Groppa, S.
    Klotz, L.
    Meuth, S. G.
    Tackenberg, B.
    Stoppe, M.
    Bergh, F. Then
    Tumani, H.
    Kuempfel, T.
    Stangel, M.
    Heesen, C.
    Wildemann, B.
    Paul, F.
    Bayas, A.
    Warnke, C.
    Weber, F.
    Linker, R. A.
    Ziemann, U.
    Zettl, U. K.
    Zipp, F.
    Wiendl, H.
    Hemmer, B.
    Gold, R.
    Salmen, A.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 554 - 556
  • [33] Disease-Modifying Treatment in Progressive Multiple Sclerosis
    Ciotti, John Robert
    Cross, Anne Haney
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2018, 20 (05)
  • [34] Disease-Modifying Agents for the Treatment of Cystic Fibrosis
    Tait, Bradley D.
    Miller, John P.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 49, 2014, 49 : 317 - 330
  • [35] Disease-Modifying Treatment of Amyotrophic Lateral Sclerosis
    Schultz, Jordan
    AMERICAN JOURNAL OF MANAGED CARE, 2018, 24 (15): : S327 - S335
  • [36] OSTEOARTHRITIS AND HYALURONAN - PALLIATIVE OR DISEASE-MODIFYING TREATMENT
    GHOSH, P
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 1993, 22 (06) : 1 - 3
  • [37] Are the high-costs of MS disease-modifying therapies justified?
    Giovannoni, Gavin
    Hawkes, Chris
    Levy, Michael
    Waubant, Emmanuelle
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 20 : A3 - A5
  • [38] AAN unveils new guidelines for MS disease-modifying therapy
    Bittner, Stefan
    Zipp, Frauke
    NATURE REVIEWS NEUROLOGY, 2018, 14 (07) : 384 - 386
  • [39] Disease-modifying therapies alter gut microbial composition in MS
    Sand, Ilana Katz
    Zhu, Yunjiao
    Ntranos, Achilles
    Clemente, Jose C.
    Cekanaviciute, Egle
    Brandstadter, Rachel
    Crabtree-Hartman, Elizabeth
    Singh, Sneha
    Bencosme, Yadira
    Debelius, Justine
    Knight, Rob
    Cree, Bruce A. C.
    Baranzini, Sergio E.
    Casaccia, Patrizia
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2019, 6 (01):
  • [40] US health insurance is an obstacle to disease-modifying treatments in MS
    Bourdette, Dennis
    Patti, Francesco
    NEUROLOGY, 2016, 87 (04) : 346 - 347
12345